Richard Volckmann
Overview
Explore the profile of Richard Volckmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
5519
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Langenberg K, van Hooff S, Koopmans B, Strijker J, Kholosy W, Ober K, et al.
Eur J Cancer
. 2025 Feb;
218:115275.
PMID: 39954414
Introduction: Despite druggable events to be present in 80 % of neuroblastomapatients within the Princess Máxima Center precision medicine program 'iTHER', clinical uptake of treatment recommendations has been low, and...
2.
van der Zalm A, Dings M, Manoukian P, Boersma H, Janssen R, Bailey P, et al.
Commun Med (Lond)
. 2024 May;
4(1):89.
PMID: 38760583
Background: Despite the advent of neoadjuvant chemoradiotherapy (CRT), overall survival rates of esophageal adenocarcinoma (EAC) remain low. A readily induced mesenchymal transition of EAC cells contributes to resistance to CRT....
3.
Schoenmaker T, Zwaak J, Loos B, Volckmann R, Koster J, Eekhoff E, et al.
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047804
Fibrodysplasia Ossificans Progressiva (FOP) is a very rare genetic disease characterized by progressive heterotopic ossification (HO) of soft tissues, leading to immobility and premature death. FOP is caused by a...
4.
Orth M, Surdez D, Faehling T, Ehlers A, Marchetto A, Grossetete S, et al.
Cell Rep
. 2022 Dec;
41(10):111761.
PMID: 36476851
Ewing sarcoma (EwS) is characterized by EWSR1-ETS fusion transcription factors converting polymorphic GGAA microsatellites (mSats) into potent neo-enhancers. Although the paucity of additional mutations makes EwS a genuine model to...
5.
Langenberg K, Meister M, Bakhuizen J, Boer J, van Eijkelenburg N, Hulleman E, et al.
Eur J Cancer
. 2022 Oct;
175:311-325.
PMID: 36182817
iTHER is a Dutch prospective national precision oncology program aiming to define tumour molecular profiles in children and adolescents with primary very high-risk, relapsed, or refractory paediatric tumours. Between April...
6.
Westerhout E, Hamdi M, Stroeken P, Nowakowska N, Lakeman A, van Arkel J, et al.
Cancer Res
. 2022 Jul;
82(14):2657.
PMID: 35844173
No abstract available.
7.
Strating E, Wassenaar E, Verhagen M, Rauwerdink P, van Schelven S, de Hingh I, et al.
Br J Cancer
. 2022 Mar;
127(1):145-155.
PMID: 35296803
Background: In colorectal cancer (CRC), the consensus molecular subtype 4 (CMS4) is associated with therapy resistance and poor prognosis. Clinical diagnosis of CMS4 is hampered by locoregional and temporal variables...
8.
Laoukili J, Constantinides A, Wassenaar E, Elias S, Raats D, van Schelven S, et al.
Br J Cancer
. 2022 Feb;
126(12):1824-1833.
PMID: 35194192
Background: Peritoneal metastases (PM) in colorectal cancer (CRC) are associated with therapy resistance and poor survival. Oxaliplatin monotherapy is widely applied in the intraperitoneal treatment of PM, but fails to...
9.
Verly I, Matser Y, Leen R, Meinsma R, Fiocco M, Koster J, et al.
JCO Precis Oncol
. 2022 Jan;
6:e2000447.
PMID: 35085004
Purpose: Elevated urinary 3-methoxytyramine (3MT) level at diagnosis was recently put forward as independent risk factor for poor prognosis in neuroblastoma. Here, we investigated the biologic basis underlying the putative...
10.
Westerhout E, Hamdi M, Stroeken P, Nowakowska N, Lakeman A, van Arkel J, et al.
Cancer Res
. 2021 Dec;
82(3):484-496.
PMID: 34853072
Cancer therapy frequently fails due to the emergence of resistance. Many tumors include phenotypically immature tumor cells, which have been implicated in therapy resistance. Neuroblastoma cells can adopt a lineage-committed...